JNJ-78278343 for Prostate Cancer
What You Need to Know Before You Apply
What is the purpose of this trial?
This trial tests a new medicine that helps immune cells find and kill advanced prostate cancer cells. It is for patients whose cancer has spread and does not respond to usual treatments. The medicine works by linking immune cells to cancer cells, prompting an immune attack on the cancer.
Will I have to stop taking my current medications?
You will need to stop any other anticancer treatments at least 2 weeks before starting the study drug. If you are on medications that suppress the immune system, you must stop them 3 days before the first dose. The protocol does not specify about other medications, so it's best to discuss with the study team.
Who Is on the Research Team?
Janssen Research & Development, LLC Clinical Trial
Principal Investigator
Janssen Research & Development, LLC
Are You a Good Fit for This Trial?
This trial is for men with advanced prostate cancer that has spread, who have already tried at least one type of hormone therapy or chemotherapy. They should be relatively healthy and active (ECOG status 0-1), not have major heart issues, clotting diseases, infections like hepatitis B/C or HIV, autoimmune diseases, lung problems, or any other cancers in the last two years.Inclusion Criteria
Exclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Dose Escalation
Participants receive escalating doses of JNJ-78278343 to determine the recommended phase 2 dose(s) (RP2Ds)
Dose Expansion
Participants receive JNJ-78278343 at the recommended phase 2 dose(s) determined in Part 1
Follow-up
Participants are monitored for safety and effectiveness after treatment
What Are the Treatments Tested in This Trial?
Interventions
- JNJ-78278343
Find a Clinic Near You
Who Is Running the Clinical Trial?
Janssen Research & Development, LLC
Lead Sponsor
Joaquin Duato
Janssen Research & Development, LLC
Chief Executive Officer since 2022
MBA from ESADE, Master of International Management from Thunderbird School of Global Management
Dr. Jijo James, MD
Janssen Research & Development, LLC
Chief Medical Officer since 2014
MD from St. Johns Medical College, MPH from Columbia University